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ABSTRACT.
Purpose: Primary open-angle glaucoma (POAG) has been reported to occur more frequently in
Africans, and to follow amore severe course compared toEuropeans.We aimed to describe characteristics
of POAG presentation and treatment across three ethnic groups from Africa and one from Europe.
Methods: We ascertained 151 POAG patients from South African Coloured (SAC) and 94 South
African Black (SAB) ethnicity from a university hospital in South Africa. In Tanzania, 310 patients
were recruited from a university hospital and a referral hospital. In the Netherlands, 241 patients of
European ancestry were included. All patients were over 35 years old and had undergone an extensive
ophthalmic examination. Patients were diagnosed according to the ISGEO criteria. A biogeographic
ancestry analysis was performed to estimate the proportion of genetic African ancestry (GAA).
Results: The biogeographic ancestry analysis showed that the median proportion of GAA was
97.6% in Tanzanian, 100% in SAB, 34.2% in SAC and 1.5% in Dutch participants. Clinical
characteristics at presentation for Tanzanians, SAB, SAC and Dutch participants, respectively: mean
age: 63, 57, 66, 70 years (p < 0.001); visual acuity in the worse eye: 1.78, 1.78, 0.3, 0.3 LogMAR
(p < 0.001); maximum intraocular pressure of both eyes: 36, 34, 29, 29 mmHg (pANOVA < 0.001);
maximum vertical cup to disc ratio (VCDR) of both eyes: 0.90, 0.90, 0.84, 0.83 (p < 0.001); mean
central corneal thickness: 506, 487, 511, 528 lm (p < 0.001). Fourteen percent of Tanzanian patients
presented with blindness (<3/60 Snellen) in the better eye in contrast to only 1% in the Dutch.
Conclusion: In this multi-ethnic comparative study, Sub-Saharan Africans present at a younger
age with lower visual acuity, higher IOP, larger VCDR, than SAC and Dutch participants. This
indicates the more progressive and destructive course in Sub-Saharan Africans.
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Introduction
Glaucoma, a heterogeneous group of
eye disorders leading to neurodegener-
ation of the optic nerve, is a leading
cause of irreversible blindness in the
world. Various epidemiologic studies
have demonstrated that primary open-
angle glaucoma (POAG) prevalence is
the highest in persons from sub-Saha-
ran African (SSA) ancestry. In 2015,
there were an estimated 10 million
African people suffering from POAG,
compared to 58 million people world-
wide (Kapetanakis et al. 2016). People
from SSA ancestry are three times
more likely to develop POAG than
Europeans (Tham et al. 2014). The
prevalence of POAG is not only higher
in the Africa-derived population, blind-
ness is also four times more frequent in
African glaucoma patients compared
to Western Europeans (Kyari et al.
2013). Known risk factors to explain
the poor visual prognosis in these
patients are as follows: little disease
awareness, poor adherence to treat-
ment and reluctance to the acceptance
of surgery. Factors causing a delay in
adequate glaucoma treatment are lim-
ited affordability, accessibility and
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availability of eye care and medication.
These socio-economic and socio-geo-
graphic conditions may explain a part
of the poor visual prognosis in people
from SSA ancestry, but an earlier onset
and more severe disease course have
also been implicated as possible risk
factors in POAG (Wilensky et al. 1978;
Martin et al. 1985; Wilson et al. 1985).
In this study, we evaluated the ethnic
risk factor for POAG and the influence
of a poor healthcare system in devel-
oping countries on the visual prognosis
in POAG. We compared the clinical
characteristics of POAG presentation
across three ethnic groups from SSA
(one from Tanzania and two from
South Africa) ancestry and one Euro-
pean population (the Netherlands).
Methods
Study population
Genetics in glaucoma patients of African
descent (GIGA) study
The GIGA study is a case-control study
comprisingopen-angleglaucomapatients
and healthy subjects from South Africa
and Tanzania. The study was conducted
in a clinical setting and participants were
ascertained at the ophthalmology clinics
of the Groote Schuur Hospital in Cape
Town, South Africa and from two hospi-
tals in Tanzania: Muhimbili National
HospitalandCCBRTDisabilityHospital
in Dar es Salaam. In all hospitals, the
study was incorporated in the daily clin-
ical routine and participants were
recruited consecutively from the outpa-
tient department (general and glaucoma
clinics). Participants were examined by a
local glaucoma specialist for eligibility. In
total, 697 patientsmet the inclusion crite-
ria of the study. Inclusion criteria were as
follows: participants of South African
Black (SAB), admixed South African
Coloured (SAC; Adhikari 2005) and
Tanzanian descent, over 35 years of age,
and diagnosed with POAG according to
the InternationalSocietyofGeographical
and Epidemiological Ophthalmology
(ISGEO) classification (Foster et al.
2002). All other types of glaucoma,
including secondary causes or nar-
row/closed angle glaucoma were
excluded. Control subjects that were
simultaneously recruited have not been
analysed in the current study.
All participants provided written
informed consent in accordance with
the ethical standards as stated in the
Declaration of Helsinki. The study
protocol for the GIGA study was
approved by the Institutional review
boards of the Erasmus MC, Muhimbili
University of Health and Allied
Sciences, and the University of Cape
Town. Additionally, the Medical
Research Coordination Committee of
the Tanzania National Institute for
Medical Research (NIMR) accepted
the study protocol.
Groningen longitudinal glaucoma study
(GLGS)
A sample of 241 white European
ancestry POAG cases was drawn from
the Groningen Longitudinal Glaucoma
Study (GLGS), a prospective cohort
study performed in a clinical setting.
The objectives, methods, rationale and
study design have been described ear-
lier (Heeg et al. 2005). Briefly, the
GLGS is an institutional review
board-approved observational
prospective follow-up study of 875
patients with established or suspect
glaucoma who visited the glaucoma
outpatient service of the University
Medical Center Groningen between
July 1, 2000 and June 30, 2001 and
who provided informed consent, in
accordance with the declaration of
Helsinki. The study included conven-
tional perimetry, frequency doubling
technique perimetry (FDT; Carl Zeiss
Meditec AG, Jena, Germany) and laser
polarimetry (GDx; Laser Diagnostic
Technologies, San Diego, CA). Out of
the initial 875 patients, 452 were clas-
sified as having glaucoma (including
primary and secondary open angle and
angle closure glaucoma). Of these 452
patients with glaucoma, the disease in
372 of them was classified by using
standard automated perimetry [Hum-
phrey Field Analyzer (HFA); Carl
Zeiss Meditec Inc., Dublin, CA,
USA]. The Goldmann perimeter
(Haag Streit AG, Bern, Switzerland)
was used in 80 patients, who were
excluded from this analysis. For the
aim of the current study, only Euro-
pean ancestry POAG cases diagnosed
according to ISGEO Category 1 diag-
nosis were included in the analysis,
leaving 241 patients.
Estimation of genetic ancestry
To determine the proportion of genetic
African ancestry in the GIGA study
participants, all POAG patients were
genotyped using either Illumina
HumanOmniExpressExome or the Illu-
mina HumanOmni2.5Exome beadchip.
The full procedures of this analysis
have been described earlier (Bonnemai-
jer et al. 2017). In brief, the genotypes
of the GIGA samples were merged
with reference populations from the
1000 Genomes project phase 3.
Unlinked single nucleotide polymor-
phisms were selected and used for
biographic ancestry estimation using
the program ADMIXTURE (v 1.23) for
K = 3 putative ancestral populations
(African, European and Asian)
(Alexander et al. 2009).
For the GLGS cohort, ADMIXTURE (v
1.3) was used to estimate the ancestry
components (Alexander et al. 2009).
This cohort was genotyped using Glo-
bal Screening Array Beadchip and its
samples were merged with reference
populations from the 1000 Genomes
project phase 3. The procedure to
calculate the biographic ancestry was
similar to the methods applied in the
GIGA study, as described above.
Ophthalmic examination in the GIGA
study
The complete eye examination in
GIGA included visual acuity (VA) by
Snellen or Tumbling E chart at 6 m
with and without refractive correction,
intraocular pressure (IOP) measure-
ment with Goldmann applanation
tonometry, slit-lamp examination
including peripheral anterior chamber
depth assessment by the Van Herick
method, indirect gonioscopy, fun-
doscopy for optic nerve head examina-
tion and digital fundus photography
centred on the optic nerve by means of
a Canon CF-60DSi (Canon Inc, Tokio,
Japan) fundus camera (South Africa)
or Optomed Smartscope M5 EY3
(Optomed Ltd, Oulu, Finland) hand-
held fundus camera (Tanzania).
Central corneal thickness (CCT) was
measured after topical instillation of
anaesthesia with an ultrasound pachy-
meter. In South Africa, 10 readings
were automatically captured in both
eyes with an A-scan/pachymeter OcuS-
can RxP (Alcon Laboratories, Inc., Ft.
Worth, TX, USA). In Tanzania, the
handheld ultrasonic pachymeter Palm-
scan P2000FP (Micro Medical
Devices Inc, Calabasas, CA, USA)
was used and five readings were taken
manually in both eyes. As the intra-
individual variance was small, and to
conform with the CCT measurement
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methods applied in GLGS these values
were averaged.
Visual field testing was performed,
VA permitting, with either the Sita
Fast strategy (Humphrey Field Ana-
lyzer (HFA) 24-2, Carl Zeiss Meditec,
Inc., Dublin, CA, USA) or fast thresh-
old strategy (Medmont M700 perime-
ter, Medmont, Camberwell, Victoria,
Australia Studio and Optopol PTS
1000, Optopol Technology, Zawiercie,
Poland). A definite visual field defect
consistent with glaucoma was defined if
the glaucoma hemifield test graded
‘outside normal limits’ or if a cluster
of three contiguous points was
observed at the 5% level of the pattern
deviation plot, including at least one of
these points < 1%. Visual field defects
were not attributed to glaucoma in the
presence of media opacities or non-
glaucomatous disease that could
explain the visual field abnormality.
All relevant clinical data relating to
the ophthalmic history, course of
POAG, presence of other types of
glaucoma, treatment and any eye oper-
ations were collected and recorded
from the medical charts. Lastly, a
questionnaire was filled out by an
English/Kiswahili speaking interviewer
covering demographic data, self-re-
ported ethnicity, medication, family
history and medical history.
Ophthalmic examination in GLGS
The complete eye examination in GLGS
included a VA by Snellen with and
without refractive correction, IOP mea-
surement with Goldmann applanation
tonometry, slit-lamp examination includ-
ing gonioscopy, and fundoscopy foroptic
nerve head (ONH) examination. The
ONH was described by using the VCDR
as long as the rim was uninterrupted; if
interrupted the ONH classified as having
a notch (interrupted either inferiorly or
superiorly) or (sub) total excavation (in-
terrupted both inferiorly or superiorly).
The CCT was measured with an ultra-
sound pachymeter (Tomey SP-3000;
Tomey Ltd, Nagoya, Japan) after the
topical instillation of an anaesthetic eye
drop. The standard white on white HFA
30–2 Sita Fast algorithm was used for
perimetric testing (Carl Zeiss Meditec
Inc.).
Classification of a definite visual
field defect consistent with glaucoma
was defined as in the GIGA study (see
aforementioned criteria). Patients with
a reproducible visual field defect in at
least one eye were classified as glau-
coma patients. The first test, however,
was left out of consideration because of
any learning effects. Therefore, at least
three visual fields were required for the
diagnosis of glaucoma.
Inclusion criteria
All patients (GIGA + GLGS) were
categorized as glaucomatous according
to the ISGEO classification for open-
angle glaucoma (Foster et al. 2002). In
GIGA, detailed grading of the ONH
was performed by one general ophthal-
mologist (AAT) and one glaucoma
specialist (HGL). They independently
interpreted fundus images and visual
field results while being masked to
other clinical information. In case of
any discrepancy between the two gra-
ders, adjudication was solved by con-
sensus. If no consensus was reached,
participants were excluded. In GLGS,
all visual fields were assessed by two
independent graders, being a general
ophthalmologist (GPH) and a glau-
coma specialist (NMJ). Any discrepan-
cies were discussed and solved by
consensus. The ONH was assessed
clinically by one of three glaucoma
experts (NMJ, LJB, PH; for further
details, see Heeg et al 2005). The
original visual field and ONH classifi-
cations were integrated into ISGEO
classification for the current study.
Category 1 or 2 ISGEO criteria were
required for the diagnosis of glaucoma.
The highest level of evidence (Category 1
diagnosis) requires a definite visual field
defect, as mentioned above, and loss of
the neuroretinal rimwith aVCDR ≥ 0.7,
or VCDR asymmetry ≥ 0.2 (both values
represented the 97.5th percentile for the
normal population (Buhrmann et al.
2000; Wolfs et al. 2000; Rotchford et al.
2003). Category 2 diagnosis requires a
severely damagedONH in the absence of
a visual field test, that is, a VCDR ≥ 0.8
or VCDR asymmetry ≥ 0.3 (both values
determined by the 99.5th percentile for
the normal population (Buhrmann et al.
2000; Wolfs et al. 2000; Rotchford et al.
2003). In addition, patients with POAG
demonstrated an open angle on gonio-
scopy.
Data analysis
Two time points play a role in our
study: the time at which the patient
presented with glaucoma at one of the
recruitment hospitals, further referred
to as ‘presentation’ and the time at
which the patient was included in the
study further referred to as ‘inclusion’.
To describe the mode of presentation,
data on age at presentation, IOP,
VCDR and visual acuity were collected
from the medical charts going back to
the timepoint the patient was newly
diagnosed with POAG. At inclusion
additional information was recorded,
that is age at inclusion, CCT, family
history, medical history (Diabetes mel-
litus, cardiovascular disease) and the
medical file was reviewed to collect
information on glaucoma surgeries and
treatment that has taken place in the
time interval from presentation to
inclusion. In some cases, presentation
and inclusion coincided. In the GIGA
study 298 (53.7%) patients and in the
GLGS 67 (27.8%) patients were
included in the study within one year
from presentation. For IOP and
VCDR the maximum value of both
eyes was used in the analysis. For CCT
the average of both eyes was taken.
Statistical analysis
Quantitative differences measured on a
continuous scale between ethnic groups
were analysed by one-way analysis of
variance (ANOVA) and when reported
statistically significant followed up with
aTukey’sDpost hoc test. For variables in
which the homogeneity of variance
assumption between the groups was vio-
lated, a Welch’s ANOVA test was con-
ducted. Statistically significant Welch
ANOVA results were followed up by a
Games–Howell post-hoc test. Variables
that did not follow a parametric distribu-
tion were analysed by Kruskal–Wallis H
test. The medians of the Kruskal–Wallis
H test were interpreted when the distri-
butionswere similar for all ethnic groups.
Interquartile ranges are reported as first
to third quartile defined by the Tukey
hinge method. Statistical analysis was
performed with SPSS Statistics 24 (SPSS,
Chicago, IL, USA) and RSTUDIO (RStu-
dio: Integrated Development Environ-
ment for R. RStudio, PBC, Boston, MA
URL http://www.rstudio.com/).
Results
Of the 743 glaucoma patients enrolled
in the GIGA study, 555 patients met
the ISGEO criteria (Category 1 diag-
nosis: 230 patients; Category 2 diagno-
sis: 325 patients) after review of fundus
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photos and visual field results, and
these 555 were included in the current
analysis. They comprised of 310 Tan-
zanian, 94 South African black (SAB)
and 151 South African Coloured
(SAC) POAG patients. For the GLGS,
all 241 included subjects had an
ISGEO Category 1 diagnosis. We
assessed the proportion of genetic
African ancestry among the GIGA
patients. The median proportion of
genetic African ancestry was similar in
the Tanzanian and SAB groups (97.6%
and 100% respectively) but was greatly
reduced in the SAC group (34.2%), as
was to be expected from an admixed
population. In the Dutch patients from
GLGS, the median proportion of
genetic European ancestry was 97.4%
and the African ancestry was 1.5%.
Clinical characteristics of POAG
presentation
The clinical characteristics of POAG
presentation (i.e. the time the patient
presented at the hospital and was
diagnosed with POAG) in Tanzanians,
SAB, SAC and the Dutch are presented
in Table 1. The mean age was statically
significant different between the four
ethnic groups (p < 0.001) and ranged
from 57.0 years in SAB patients to
69.7 years in the Dutch (Fig. 1A). In
particular Tanzanian and SAB patients
presented at younger age compared to
SAC and Dutch patients. The maximal
IOP of both eyes was the highest in the
Tanzanian group (36.2 mmHg) and the
IOP was statically significantly higher
in Tanzanian and SAB compared to
SAC and the Dutch (Fig. 1B). The
maximal VCDR of both eyes was
statistically significant different
between the four ethnic groups
(p < 0.001) and ranged from 0.80 in
SAC and Dutch patients to 0.90 in
Tanzanian and SAB patients (Fig. 1C).
Tanzanians (1.78 LogMar) and SAB
(1.78 LogMar) patients had a statisti-
cally significantly worse visual acuity in
the worse-seeing eye than the SAC
(0.30 LogMar) and Dutch (0.30 Log-
Mar) patients (Fig. 1E). The visual
acuity in the better-seeing eye was
statically significant higher in the
Dutch (0.00 LogMar) than in the three
African ancestral groups (Fig. 1F). To
eliminate bias due to other causes of
reduced vision we executed a sensitivity
analysis by excluding all subjects with
an additional diagnosis that might have
affected their visual acuity (e.g catar-
act) or had a cataract operation
between presentation and inclusion in
the study. For Tanzanian and SAC
patients, the median visual acuity in the
worse-seeing eye did not change after
excluding probable other causes of
vision loss (being 1.78 LogMar (IQR
0.5–2.5) and 0.3 LogMar (IQR 0.2–
0.6), respectively). After excluding
other probable causes of vision loss in
the SAB and Dutch group, the median
visual acuity in the worse-seeing eye at
presentation improved to 0.89 LogMar
(IQR 0.3–2.5; not significant) and 0.2
LogMar (IQR 0.0–0.3; p < 0.05),
respectively. The mean visual acuity in
the better-seeing eye did not change
after excluding other causes of vision
loss. Binocular blindness at presenta-
tion, defined by WHO criteria as a
VA < 3/60 in the better eye, was
reported in 13.5% of Tanzanian, 18.1
% in SAB, 4.1% in SAC and 1.7% in
Dutch patients. The proportion of
binocular blindness at presentation
was distributed equally among male
and female patients in all ethnic groups
(p > 0.05). Older age at presentation
was associated with higher odds of
binocular blindness in Tanzanian
(OR = 1.45/10 year increase in age,
95%CI = 1.06–1.98, p = 0.02) and
SAB (OR = 1.80/10 year increase in
age, 95%CI = 1.13–2.89, p = 0.02).
Monocular blindness at presentation
was reported in 51.6% of Tanzanian,
48.9 % in SAB, 24.5% in SAC and
16.2% in Dutch patients. The central
corneal thickness was statically signif-
icantly thinner in the African groups
than in the Dutch (p ≤ 0.001; Fig. 1G)
and thinnest in the SAB (487µm;
Table 1).
A questionnaire assessment was per-
formed at the inclusion in the studies to
evaluate demographic characteristics
and heritable risk of glaucoma
(Table 1). Reported first-degree family
history of glaucoma ranged from 17%
in the SAB to 28% in the Tanzanian
group (p < 0.05). The self-reported
prevalence of diabetes mellitus was
the highest in SAC (33.1%). Adjust-
ments for potential confounding by age
and sex showed that the difference in
prevalence of diabetes mellitus between
SAC and Tanzanian and between SAC
and the Dutch was statistically signif-
icant after multiple testing correction
(ORSAC vs. TZ = 3.98, 95%CI = 2.40–
6.62, p < 0.001; ORSAC vs. DUT = 3.27,
95%CI = 1.93–5.43, p < 0.001). Car-
diovascular disease prevalence was also
the highest in SAC patients followed by
SAB and the Dutch. Tanzanians had a
significantly lower prevalence com-
pared to the other groups when adjust-
ing for age, sex and multiple testing
(ORTZ vs. SAB = 0.25, 95%CI = 0.15–
0.41, p < 0.001; ORTZ vs. SAC = 0.32,
95%CI = 0.21–0.50, p < 0.001;
ORTZ vs. DUT = 0.56, 95%CI = 0.39–
0.81, p = 0.003). Adjustments for age
and sex also indicated a statistically
significant higher cardiovascular dis-
ease prevalence in SAB compared to
the Dutch (OR = 2.30, 95%CI = 1.36–
3.90, p = 0.02).
Glaucoma surgery in Sub-Saharan Africa
Next, we examined the frequency of
different types of surgical interventions
for glaucoma that had been performed
between presentation and inclusion
among African groups. As the inci-
dence of glaucoma surgery may
depends on the follow-up duration,
we calculated the time intervals
between presentation and inclusion.
Median time from presentation to
inclusion was 0.3 year (IQR 0.01–1.2)
in Tanzanian, 3.1 years (IQR 0.7–8.4)
in SAB, 2.9 years (IQR 0.8–8.1) in
SAC.
Laser trabeculoplasty was only per-
formed in one SAC patient that had
received Argon laser trabeculoplasty.
Trabeculectomy (TE) had been more
frequently performed in the Tanzani-
ans (37.1% of patients; n = 145 eyes)
followed by SAB (33% of patients,
n = 44 eyes) and SAC (21.9% of
patients, n = 42 eyes). Taking into
account the time interval between pre-
sentation and inclusion, the incidence
rate of TE was 0.76 per person-year in
Tanzanians, 0.11 TE per person-year in
SAB and 0.06 per person-year in the
SAC. The median time from presenta-
tion to TE was 53 days (IQR 18–211)
in Tanzanian, 300 days (IQR 105–967)
in SAB and 314 days (IQR 150–984) in
SAC patients. TE combined with pha-
coemulsification, so-called phacotra-
beculectomy had also been performed
in Tanzanians, as well as in SAC
patients. Among the Tanzanian
patients that had undergone a TE,
26.1% (n = 33 eyes) had had a com-
bined procedure, whereas in the SAC
patients, only 9.1% (n = 4 eyes) of
patients that had undergone a TE had
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had a combined procedure. Different
types of adjunctive antimetabolites had
been used in the African groups during
the TE procedures. A total of 231 eyes
had undergone a TE in the African
groups, of which 37 eyes had under-
gone combined phacotrabeculectomy.
5-fluorouracil had been used in 43%
(n = 99) of eyes, whereas mitomycin-C
had been used in 36% (n = 84) of eyes
and beta-radiation had been applied in
3% (n = 7) of eyes. The differences
between the types of antimetabolites
that had been used among the African
groups have been displayed in Fig. 2.
Discussion
This study compared clinical and
demographic characteristics of POAG
presentation in sub-Saharan African
populations with a European popula-
tion. We found that Tanzanian and
SAB patients presented at a younger
age than the Dutch (7–13 years ear-
lier), and in a more advanced disease
stage (VCDR 0.9) compared to Dutch
patients. The IOP was 5–7 mmHg
higher and the CCT was more than
20 µm thinner in the Tanzanian and
SAB groups than in the Dutch. The
presenting visual acuity in the better-
seeing eye was approximately 15
ETDRS letters (0.3 LogMar units)
lower in the Tanzanian group than in
the Dutch group; 14% of Tanzanian
patients presented with blindness in the
better-seeing eye in contrast to 1% in
the Dutch. These data emphasize the
severe presentation of POAG in SSA at
middle age.
The relatively younger age at pre-
sentation in Tanzanian and SAB and
the more structural and functional
damage of the optic nerve head impli-
cates that the disease has an earlier age
of onset and runs a more severe course
in African patients. Also, thinner CCT
affects Goldmann applanation tonom-
etry readings and leads to an underes-
timation of IOP. Our data supports
other studies, that the CCT in SSA
populations is thinner than in Euro-
peans (SAB: 487 µm, Dutch: 528 µm,
p < 0.001). We therefore conclude that
the differences in IOP between
Tanzanian, SAB and Dutch patients
are probably even higher than noted
due to differences in CCT.
The higher IOP might have a more
destructive effect on the optic nerve
head in African populations. Studies
have suggested that larger optic disc
diameters may be associated with
increased vulnerability to pressure-in-
duced deformation (Bellezza et al.
2000; Burgoyne et al. 2005). Investiga-
tion into ethnic differences in the
anatomy of the optic nerve head
showed larger optic discs in African
individuals (Girkin et al. 2010). In this
context, the higher presenting IOP
observed in the African populations
may have a potentially more damaging
effect on the optic nerve head. How-
ever, clinical studies could not validate
this hypothesis (Jonas et al. 2004;
Zangwill et al. 2005).
Our study found a higher VCDR at
presentation in the African derived
populations compared to SAC and
Dutch participants, suggesting more
advanced glaucomatous damage in
the prior. As VCDR measurements










N = 241 P-value
Year of presentation, median (IQR) 2013 (2012 - 2014) 2010.50 (2006 - 2013) 2011 (2005- 2013) 1999 (1998 2001)
Age at presentation,
mean (years)  SD
62.7  11.0 57.0  12.0 65.7  10.0 69.7  11.7 F* (3, 312.155)
= 31.255
p < 0.001
Female, % (n) 36.8 (114) 51.1 (48) 55.6 (84) 44.8 (108) <0.001†
IOP at presentation
(mmHg), maximal OU  SD




maximal OU  SD





in worse eye, median (IQR)





in better eye, median (IQR)
0.3 (0.2–0.8) 0.2 (0.2–0.6) 0.2 (0.2–0.3) 0.0 (0.0–0.2) v*‡ (3) = 95.190
p < 0.001
CCT, mean(µm) OU  SD 506.2  33.8 487.1  38.4 510.7  34.7 528.1  40.0 F§ (3, 509)
= 20.171
p < 0.001
Family history of glaucoma, % (n)¶ 28.4 (88) 17.0 (16) 17.2 (26) 20.7 (43) 0.015†
Diabetes mellitus, % (n)¶ 11.6 (36) 18.1 (17) 33.1 (50) 13.7(33) <0.001†
Cardiovascular disease, % (n)¶ 31.3 (97) 62.8 (59) 64.9 (98) 53.3 (126) <0.001†
IQR = interquartile range; OU = both eyes; SD = standard deviation.
* p-value obtained from a one-way Welch ANOVA.
† p-value obtained from a chi-square test.
‡ p-value obtained from a Kruskall–Wallis H test.
§ p-value obtained from a one-way ANOVA.
¶ Parameters were assessed at inclusion in the study, the mean age ( SD) at inclusion was: Tanzanian 63.5(10.8); South African Black 61.5 (11.2);
South African Coloured 70.5 (10.3) and Dutch 71.6 (11.4) years.
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are dependent on disc size (Garway-
Heath et al. 1998), ethnic differences in
disc size should ideally be taken into
consideration when interpreting
VCDR between ethnic groups. As
measurements of the optic disc size
were not available, we compared the
VCDR to the normal distribution of
VCDR in the population using refer-
ence distributions of Tanzania (Buhr-
mann et al. 2000), South Africa
(Rotchford et al. 2003) and the
(A) (B) (C)
(D) (E) (F)
Fig. 1. Clinical characteristics at presentation. (A) age at presentation in years (mean, 95% CI). (B) maximal intraocular pressure of both eyes in
mmHg (mean, (95% CI). (C) maximal vertical cup disc ratio of both eyes (mean, 95% CI). (D) visual acuity in worse eye in LogMar (median, IQR). €
visual acuity in the better eye in LogMar (median, IQR). (F) central corneal thickness in lm (mean, 95% CI).
Fig. 2. Antimetabolite use during trabeculectomy procedures.
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Netherlands (Wolfs et al. 2000). VCDR
readings exceeding the 97.5th percentile
are generally considered abnormal. The
mean of the VCDR values recorded at
presentation in this study surpassed the
97.5th percentile threshold in the nor-
mal population indicating that the
values were deviant from the normal
population.
Several epidemiological studies have
debated that diabetes mellitus (DM)
may be a risk factor for POAG (Song
et al. 2016). The recent rise in life
expectancy and changes in lifestyle
have contributed to a shift in disease
patterns and increasing burden of non-
communicable diseases like DM in
SSA. In our study, we observed DM
prevalence ranging from 12% in Tan-
zanian POAG patients to 33% in SAC
POAG patients. These numbers do
certainly not entail a causal relation-
ship. Conflicting evidence exists
whether POAG and diabetes are
related however a relative recent
meta-analysis showed a significant
association between POAG and dia-
betes considering data from different
study designs (Zhao et al. 2015). Given
the rising prevalence of DM in people
of SSA (Atun et al. 2017), POAG
evaluation should be warranted in
DM patients.
In Tanzanian and SAB patients, the
majority had already been monocular
blind at presentation (~50%) while
only 16% of the Dutch presented with
monocular blindness. Monocular
blindness may seem to be the trigger
for seeking care in healthcare-deprived
regions, however it is striking that 14%
of POAG patients in Tanzania visited
the clinic for the first time when already
binocularly blind. This delay further
supports the burden of poor access to
healthcare facilities which includes long
travel distances, poor financial status
but also lack of awareness of implica-
tions of the disease. The latter has been
supported by several African studies
assessing awareness levels in glaucoma
patients (Tenkir et al. 2010; Lewallen
et al. 2011). In particular studies that
examined awareness in the general
rural communities of Osun State in
Nigeria and a peri-urban community of
Abokobi in Ghana found that, despite
the high prevalence of the disease in
West Africa, only 16% and 39% of
participants respectively had heard of
the disease before (Adegbehingbe &
Bisiriyu 2008; De-Gaulle & Dako-
Gyeke 2016). In contrast, in Australia
where glaucoma is less frequent, aware-
ness levels are much higher: 73% of
respondents had heard of the disease
before (Livingston et al. 1995).
Another factor that should not be
omitted in evaluating patient delay is
the impact of the traditional healers
who can play a pivotal role in the
postponement to seek medical care.
And above all ophthalmologists, opto-
metrists and assistant medical officers
of ophthalmology (AMOO) are scarce
and medical instruments and the access
to medication can be challenging.
Interestingly, also in the Dutch popu-
lation, 1% of POAG presented with
binocular blindness. This indicates that
an asymptomatic chronic disease may
lead to patient delay even when the
aforementioned healthcare restrictions
are not present (Rossetti et al. 2015).
Thus, health care deprivation and
socio-economic status seem in all pop-
ulations independent risk factors for
late presentation of POAG.
This study also observed differences
in surgical treatment strategies among
African groups. TE was performed in
over one third of Tanzanians and SAB.
In particular Tanzanian patients
underwent TE more rapidly after initial
diagnosis (median 53 days) compared
to SAB and SAC. The more limited
healthcare settings in Tanzania with
less availability, accessibility and
affordability of topical medication
compared to South Africa may lead
to an earlier surgical intervention
instead of medical treatment. Also,
the lifelong use of topical medication
is not feasible in most developing
countries. Another aspect is the treat-
ment delay in Tanzanian patients, who
usually seek eye care only when at least
one eye has already been blinded. A
pragmatic approach by swift surgical
intervention may in these cases be a
solution to prevent complete blindness.
However, studies have shown that
acceptance of TE in Tanzania is poor
even when provided for free (Quigley
et al. 2000). A possible reason for this is
that TE will not help in visual recovery,
and therefore compares poorly with
cataract surgery in terms of patients’
perception (Bowman & Kirupanan-
than 2006). Moreover, TE will inevi-
tably lead to visual loss at the short
term due to associated cataract devel-
opment. Studies from South Africa and
Tanzania have suggested that
combining TE with cataract surgery
so-called phacotrabeculectomy favours
TE in practices where post-operative
follow-up is inadequate and acceptance
of glaucoma surgery is poor (Gous &
Roux 1995; Bowman et al. 2010).
Although TE has been advocated as
first line treatment in African glau-
coma, excessive scarring which may
compromise the filter function is fre-
quently seen in people of African origin
(Taubenslag & Kammer
2016).Antimetabolites like 5-fluo-
rouacil (5-FU) and Mitomycin-C
(MMC) are commonly applied during
TE and phacotrabeculectomy to pre-
vent scarring. In our study, there were
remarkable differences in the frequency
of 5-FU and MMC use between Tan-
zania and South Africa. In Tanzania
68% of procedures used intraoperative
5-FU while in South Africa 80% of
TE’s used MMC. MMC may be more
effective in lowering IOP compared to
5-FU, but is also associated with higher
rates of complications, in particular
bleb leaks, cyst formation and hypot-
ony (Singh et al. 1997). Also, MMC is
more expensive and needs to be kept
refrigerated to maintain efficacy for up
to 2 weeks in contrast to 5-FU, which
can be stored at room temperature for
several months. These latter two rea-
sons may favour 5-FU in low-income
countries with unstable electricity sup-
ply. Another anti-scarring agent which
has been used in glaucoma surgery for
many years is beta radiation. This
device has a working life over 20 years
and involves minimal maintenance
making this an attractive choice for
healthcare settings with insufficient
drugs supply and technical support.
In our study, only 8% of TE/PT
procedures in South Africa used beta
radiation as adjunctive agent. A study
from Tanzania investigated the use of
beta radiation in PT and found com-
parable IOP control in the beta radia-
tion group compared to the 5-FU
group (Dhalla et al. 2016). Although
beta radiation seems a good alternative
to 5-FU and MMC, importing radioac-
tive material in African countries may
come with additional logistical burden
making antimetabolites more easily
available. A striking observation was
that none of the African patients was
offered selective laser trabeculoplasty.
A recent trial showed that SLT is an
effective first line treatment in lowering
IOP for at least 3 years providing
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superior IOP stability, at lower costs
compared to eye drops (Gazzard et al.
2019). Other studies have shown com-
parable effectiveness of SLT in African
derived patients (30–40% reduction in
IOP; Realini et al. 2018). In SSA where
many POAG patients are unable to
sustain on topical IOP lowering med-
ication, SLT may be a viable and cost-
effective solution for treating POAG.
However, its therapeutic range in clinic
is considered lower compared to TE, as
IOP in SSA POAG patients is high, it
may be insufficient on its own in
achieving IOP at levels to prevent
glaucoma progression.
Limitations of the study are the differ-
ences in health resource settings between
Europe and Africa that may have intro-
duced bias to the stage of POAG presen-
tation. In the Netherlands, opticians and
optometrists are trained to early detect
risk factors for POAG in particularly
high IOP. This may have led to earlier
referral of POAGpatients, however even
with this surveillance taken into account
the Dutch POAG patients presented 7–
12 years later than SAB and Tanzanians
respectively in a less severe stage.Another
aspect is that the data presented here is
collected in a retrospective manner, data
regarding presentation were extracted
from themedical charts, hence these data
had been recorded by various clinicians.
Also only POAG patients that met the
ISGEO criteria were included omitting
less advanced glaucoma cases, this selec-
tion may have biased the results. More-
over, in GLGS all patients were visual
field confirmed (ISGEO 1) cases while in
GIGA visual field testing was unfeasible
in themajority of the patients, therefore a
more strict structural criterion (ISGEO2)
needed to be fulfilled for inclusion. As
structural and functional glaucomatous
changes are not interchangeable the
heterogeneity in inclusion criteria may
have introduced selection bias towards
higher VCDR at presentation in the
GIGA study. An additional limitation is
that the populationswere not recruited in
the same time frame. The GLGS cohort
had been recruited at the turn of the
millennium while the African patients
had been recruited approximately 1
decade later.
In conclusion, the present study
reinforces the notion that POAG
patients of African descent have a
more severe presentation compared to
patients from European descent; South
African Coloured patients (African,
Asian, European admixed) have a sim-
ilar mode of presentation as Euro-
peans. Our study shows that aside
from health care inequalities, that
might mediate the severity at presenta-
tion, Sub-Saharan African POAG
patients present at a younger age in a
much more advanced disease stage
with a higher IOP. This indicates that
the disease is more progressive and
destructive in Africans. Awareness of
these disease characteristics is impor-
tant in first- and second-line glaucoma
care. Pathophysiologic pathways have
yet to be discovered to explain the
higher disease load in Africans. Large
genetic studies are on their way.
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